Safety and Efficacy of the Combined Use of Ivermectin, Dexamethasone, Enoxaparin and Aspirina against COVID-19 the I.D.E.A. Protocol

Carvallo et al., Journal of Clinical Trials, 11:459, Sep 2020 (preprint)

Source

PDF

All
Studies

Meta
Analysis

Ivermectin for COVID-19

4th treatment shown to reduce risk in August 2020, now with p < 0.00000000001 from 105 studies, recognized in 24 countries.

Lower risk for mortality, ventilation, ICU, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine treatments.

5,500+ studies for 121 treatments. c19ivm.org

Prospective trial of ivermectin, dexamethasone, enoxaparin, and aspirin, showing no hospitalization for mild cases, and lower mortality for moderate/severe patients.

This is the 7th of 105 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 774 quintillion).

52 studies are RCTs, which show efficacy with p=0.00000021.

This study is excluded in the after exclusion results of meta analysis: minimal details of groups provided.

Important missing comments or errors? Let us know.

risk of death, 85.4% lower, RR 0.15, p = 0.08, treatment 1 of 32 (3.1%), control 3 of 14 (21.4%), NNT 5.5, moderate/severe patients, the only treatment death was a patient already in the ICU before treatment, primary outcome.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Carvallo et al., 15 Sep 2020, prospective, Argentina, peer-reviewed, mean age 55.7, 3 authors, dosage 36mg days 1, 8, dose varied depending on patient condition - mild 24mg, moderate 36mg, severe 48mg, this trial uses multiple treatments in the treatment arm (combined with dexamethasone, enoxaparin, and aspirin) - results of individual treatments may vary.

This Paper Ivermectin All

Safety and Efficacy of the Combined Use of Ivermectin, Dexamethasone, Enoxaparin and Aspirina against COVID-19 the I.D.E.A. Protocol

Carvallo Hector, Hirsch Roberto

From the first outbreak in Wuhan (China) in December 2019, until today (05/28/2020), the number of deaths worldwide due to the coronavirus pandemic exceeded 2.5 millions. Only in Argentina, 50,000 deaths have been confirmed so far. There haven't been so far any clear diagnostic pattern for this exceptional entity except unilateral skin involvement, early onset of symptoms, positive ANA and negative tests for Borrelia burgdorferi. Hence, we report a new case of a young Moroccan man. No treatment tested worldwide has shown unquestionable efficacy in the fight against COVID-19, according to W.H.O, NIH and NICE reports and accumulated data. Our proposal consists of the combination of drugs, based on the pathophysiology of the virus. We have designed a treatment called I.D.E.A., based on four affordable drugs already available on the pharmacopoeia in Argentina, on the following rationale: -Ivermectin (IVM) solution to lower the viral load in all stages of COVID-19. -Dexamethasone 4 mg injection, as anti-inflammatory drug to treat hyperinflammatory reaction to COVID-infection. -Enoxaparin injection as anticoagulant to treat hypercoagulation in severe cases. -Aspirin 250 mg tablets to prevent hypercoagulation in mild and moderate cases. Except for Ivermection oral solution, which was used in a higher dose than approved for parasitosis, all other drugs were used in the already approved dose and indication. Regarding Ivermectin safety, several oral studies have shown it to be safe even when used at daily doses much higher than those approved already. A clinical study has been conducted on COVID-19 patients at Eurnekian Hospital in the Province of Buenos Aires, Argentina. The study protocol and its final outcomes are described in this article. Results were compared with published data and data from patients admitted to the hospital receiving other treatments. None of the patient presenting mild symptoms needed to be hospitalized. Only one patient died (0.59% of all included patients vs. 2.1% overall mortality for the disease in Argentina today, 3.1% of hospitalized patients vs. 26.8% mortality in published data). I.D.E.A. protocol has proved to be a very effective alternative to prevent disease progression of COVID-19 when applied to mild cases, and to decrease mortality in patients at all stages of the disease with a favorable risk-benefit ratio.

CONFLICT OF INTEREST The Authors manifest no conflict of interests.

References

Amit, Usefulness of ivermectin in COVID-19 illness, doi:10.2139/ssrn.3570270

Baraka, Mahmoud, Marschke, Geary, Homeida et al., Ivermectin distribution in the plasma and tissues of patients infected with onchocerca volvulus, Eur J Clin Pharmacol, doi:10.1007/s002280050131

Batya, More evidence hydroxychloroquine is ineffective, harmful in COVID-19

Bielory, Clinical complications of heterologous antisera administration, J Wilderness Med, doi:10.1580/0953-9859-2.2.127

Bin, A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19, N Engl J Med

Botargues, Enz, Musso, Corticosteroid treatment, Evid Act. Pract Ambul, doi:10.1007/s12468-011-0007-y

Buchanan, Hirsh, Effect of aspirin on hemostasis and thrombosis, N Engl Reg Allergy Proc, doi:10.2500/108854186779045539

Bunyavanich, Do, Vicencio, Nasal gene expression of angiotensin-converting enzyme 2 in children and adults, JAMA

Caly, Julian, Druce, Mike, Catton et al., The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2, doi:10.1016/j.antiviral.2020.104787

Caly, The FDA-approved drug ivermectin inhibits the replication of, doi:10.1016/j.antiviral.2020.104787

Carvallo, Hirsch, Fajardo, Ciruzzi, Ivermectin, corticosteroids, aspirin and enoxaparin in COVID 19, Rev Educándonos Arch Arg Derm

Castro, Duarte, Carvalho, Preliminary study on the clinical effects of the treatment of acute Chikungunya fever using Ivermectin as an antiviral drug, doi:10.1186/isrctn90437126

Ceccotti, COVID 19 saliva and lingual mucosa

Ch, Ivermectin new uses for an old drug Colombian association of dermatology and dermatological surgery magazine, doi:10.1046/j.1525-1470.2001.018001063.x

Cynthia, Safety, Tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects, J Clin Pharmacol, doi:10.1177/009127002401382731

Dejong, Robert, Wachter, The risks of prescribing hydroxychloroquine for treatment of COVID-19-First, do no harm, JAMA Intern Med, doi:10.1001/jamainternmed.2020.1853

Edwards, Dingsdale, Helsby, Orme, Breckenridge, The relative systemic availability of ivermectin after administration as capsule, Tablet, and oral solution, Eur J Clin Pharmacol, doi:10.1007/bf00637608

Giovannoni, Intrinsic antiviral role of PML in flavivirus infection

Guang, Clinical and immunological features of severe and moderate coronavirus disease 2019, J Clin Invest, doi:10.1172/jci137244

Gubler, The continuing spread of West Nile virus in the western hemisphere, Clin Infect Dis, doi:10.1086/521911

Hector, None, J Clin Trials, doi:10.1016/j.antiviral.2020.104787

Hirsch, Nacucchio, Cassará, Ghirardi, Carvallo, Ivermectin its usefulness in prophylaxis, therapy and immunity against COVID 19

Hirsch, Potential benefits of aspirin and enoxaparin in COVID-19 cases

Héctor, Roberto, Francisco, Ciruzzi, Martín et al., Ivermectin, corticosteroids, aspirin and enoxaparin in the treatment of COVID 19

Jean, Hl, Thromboinflammation and the hypercoagulability of COVID-19, J Thromb Haemost

Kaiser, Our response to COVID-19 as endocrinologists and diabetologists, J Clin Endocrinol Metab, doi:10.1210/clinem/dgaa148

Kwto, Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study, doi:10.1016/s1473-3099(20)30196-1

Mehta, Mcauley, Brown, Sanchez, COVID-19: Consider cytokine storm syndromes and immunosuppression, The Lancet, doi:10.1016/s0140-6736(20)30628-0

Neil, Lopinavir-ritonavir was not effective for COVID-19, N Engl J Med

Nguyen, Evaluation of a novel West Nile virus transmission control strategy that targets Culex tarsalis with endectocide-containing blood meals, doi:10.1371/journal.pntd.0007210

Ning, Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J Thromb Haemost, doi:10.1111/jth.14851

Ogawa, The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome, J Thromb Haemost, doi:10.1111/jth.14854

Orantes, NS2B-NS3-Zika, therapeutic white for zika infection EC, Microbiol

Palmer, Stoffregen, West nile virus infection in reindeer (Rangifer Tarandus), J Infect dis, doi:10.1177/104063870401600307

Rodriguez-Morales, Cardona-Ospina, Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis, Travel Med Infect Dis, doi:10.22354/in.v25i2.922

Rodríguez-Pintó, The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients, Rheumatol, doi:10.1136/annrheumdis-2017-eular.3412

Santosh, Parmar, Anand, A review of salivary diagnostics and its potential implication in detection of COVID-19, Cureus

Silverman, Feuerstein, Herper, New data on Gilead's remdesivir show no benefit for coronavirus patients

Ziegler, SARS-CoV-2 receptor ACE2 is an interferonstimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues, Cell

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0